Please login to the form below
treatment
This page shows the latest treatment news and features for those working in and with pharma, biotech and healthcare.
Novartis reports death of two patients treated with Zolgensma
Both children died after corticosteroid medicines – which were used to reduce the risk of side effects after treatment – began to be tapered off. ... Zolgensma is currently administered intravenously, meaning treatment is limited to younger children
Latest news
-
The impact of COVID-19 on the fight against AMR
AMR occurs when bacteria, viruses, fungi and parasites change over time and no longer respond to drug treatments, making infections harder to treat and increasing the risk of severe illness and
-
Lack of evidence for AstraZeneca’s COVID-19 vaccine says UK Department of Health
Evusheld – tixagevimab co-packaged with cilgavimab – is a preventative treatment that is given before people have been exposed to the virus.
-
Novartis’ Pluvicto receives MHRA marketing authorisation to treat advanced prostate cancer
RLT is an emerging treatment option that has the potential to offer an alternative treatment pathway for some cancer patients. ... There continues to be a real and pressing need for better treatments for people with advanced prostate cancer.
-
AstraZeneca and Daiichi Sankyo receive FDA approval for lung cancer drug
There are treatment options available for those diagnosed with stage 3 NSCLC, however if a patient progresses to stage 4 – otherwise known as metastatic cancer – the options available are often limited ... time of diagnosis to ensure patients receive
-
Roche’s Xofluza issued FDA approval to treat influenza in children aged five years and older
The approval is specifically for the treatment of acute, uncomplicated influenza in otherwise healthy children aged five to less than 12 years of age who have been symptomatic for no more ... well as adolescents, and we are pleased to now offer
More from news
Approximately 25 fully matching, plus 5,513 partially matching documents found.
Latest Intelligence
-
Environment: where does the pharmaceutical industry stand?
through inefficient use of raw materials, unnecessary use of energy and water, or waste treatment – and this figure can be as high as 10%.
-
The patient voice – the value of patient-reported outcomes in HTA
Patients are now more involved in their treatment decisions, in partnership with their clinician. ... focus on itch, pain and symptom severity as measured by the patient in the treatment of psoriasis.
-
Innovation through collaboration – the importance of partnerships
By working alongside small, dynamic companies we can enable fresh ideas which improve the health of patients and society through the optimisation of existing treatments and technologies. ... treatment and rehabilitation.
-
The pharma dichotomy
While other sectors were plunged into chaos, COVID-19 highlighted our industry’s remarkable capacity for innovation, with new vaccines and treatments being developed, tested and approved in record time. ... Why, as an industry, are we incredibly
-
The importance of beliefs in creative health engagement
State clearly what the ingredients and other associations of the treatments are, and you’ll win the trust and confidence of the audience.
More from intelligence
Approximately 3 fully matching, plus 776 partially matching documents found.
Latest appointments
-
Claire Gillis appointed to newly created role of CEO of VMLY&R HEALTH
Gillis joined VMLY&R in 2020 to launch a specialist international agency, focusing on prescription pharma companies developing breakthrough treatments.
-
Mark Caulfield departs from Genomics England to take on CEO role at Barts Life Sciences
First launched in 2012, the 100, 000 Genome Project had ambitious plans to map the genomes of NHS patients to deliver treatments for those with rare inherited diseases and cancer.
-
AZ appoints Susan Galbraith as executive vice president, oncology R&D
This includes PARP inhibitor Lynparza (olaparib), third-generation tyrosine kinase inhibitor (TKI) Tagrisso (osimertinib), the recently approved MET inhibitor Orpathys (savolitinib) and Koselugo (selumetinib) – indicated for the treatment of
-
CureVac taps Klaus Edvardsen for chief development officer role
Their years of dedicated work on mRNA therapeutics positions CureVac well for bringing future treatments across a variety of indications to different patient populations.
-
Henry Skinner has been appointed as the first CEO of the AMR Action Fund
The AMR Action Fund is an initiative created to bring two to four new antibiotics to patients by 2030 – treatments which are urgently needed to address the rapid rise of antibiotic
More from appointments
Approximately 0 fully matching, plus 225 partially matching documents found.
Latest from PMHub
-
Breaking the silence: It’s time to talk about the menopause
open up the conversation, encouraging women to demand better access to care and treatment, rather than suffer in silence. ... Furthermore, 69% agreed there should be more treatments available for the symptoms of menopause.
-
emotive supports Rare Disease Day 2019
with promoting earlier diagnosis and access to novel treatments.
-
Learning about Rare Genetic Disorders on Undiagnosed Children’s Day
Children can be left facing an uncertain future and an unclear treatment pathway when they have a rare disorder. ... Numerous unknown disorders have been identified with clarity, finally providing diagnosis and treatment options to thousands.
-
Modernising the Mental Health Act: Published Today
Giving patients a voice when considering their treatment options is something we care about deeply. ... Understanding and cooperative treatment plans will improve the efficacy of administration to those with mental health difficulties.
-
After a busy first quarter, emotive welcomes five new team members
treatment of rare diseases.” said Dorothy at the end of her second day with us.
More from PMHub
Approximately 29 fully matching, plus 674 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Sanofi halts recruitment for trials assessing MS treatment
- bluebird bio reveals plans to launch two gene therapies
- ONS data reveals significant decrease in COVID-19 antibodies
- UK government’s ‘science superpower’ ambitions to fail without clear plan, Lords committee warns
- How the Royal Society’s EiR programme can help to drive UK innovation
- Bayer’s Nubeqa receives FDA approval to treat metastatic prostate cancer
- WHO releases interim statement on COVID-19 vaccination for children and adolescents
- Novartis reports death of two patients treated with Zolgensma
- The impact of COVID-19 on the fight against AMR
- NHS bowel cancer checks reach record-high following death of Dame Deborah James
- Environment: where does the pharmaceutical industry stand?
- Moderna’s Omicron booster receives MHRA approval
- AstraZeneca and Daiichi Sankyo receive FDA approval for lung cancer drug
- AbbVie and Sosei Heptares collaborate in new agreement worth up to $1.2bn
- FDA approves Incyte’s Pemazyre as first targeted drug for bile duct cancer
- WHO, UNICEF and UNAIDS launch global alliance to end AIDS in children by 2030
- Creating content to trigger behaviour change
- Strategic commitment
PMHub
EPG Health
REACH, ENGAGE & MEASURE HCPs ONLINE - Accomplish meaningful engagement via Medthority (www.medthority.com), a trusted independent medical website. Support the...
Latest intelligence
- Environment: where does the pharmaceutical industry stand?
- ...
- The communication challenge of helping he next generation to be healthier
- As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
- Are we losing sight of what the democratisation of healthcare really looks like?
- We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...
